Summary

U.S. Cell And Gene Therapy Clinical Trials Market Summary

The U.S. cell and gene therapy clinical trials market size was estimated at USD 4.64 billion in 2024 and is projected to reach USD 17.03 billion by 2033, growing at a CAGR of 15.60% from 2025 to 2033. The market is driven by an increase in R&D funding, increasing disease burden in oncology, rare genetic disorders, and neurodegenerative conditions, growing interest in cell and gene therapies for cancer treatment, and a favorable regulatory environment.

Besides, the surge in pipeline candidates with over 2,000 CGT assets is currently in development at various preclinical and clinical stages. It has benefited from substantial R&D funding provided by biopharma companies, startups, and government entities. In addition, regulatory advancements, including the FDA’s accelerated approval pathways, RMAT designations, and INTERACT meetings, support the need for cell and gene therapy initiation and development of trials.

Moreover, increased investments and M&A activities from large pharmaceutical companies are propelling the expansion of CGT trials, particularly in autologous CAR-T therapies, AAV-based gene therapies, and allogeneic platforms. Service providers and CDMOs are enhancing their CGT-specific capabilities, such as GMP vector production, viral delivery systems, and decentralized trial logistics.

U.S. Cell And Gene Therapy Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. cell and gene therapy clinical trials market report based on phase and indication.

• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiology
• CNS
• Musculoskeletal
• Infectious diseases
• Dermatology
• Endocrine, metabolic, genetic
• Immunology & inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Phase
1.2.2. Indication
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Cell and Gene Therapy Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Interest in Cell and Gene Therapy
3.2.1.2. Adoption of New Technology in Clinical Research
3.2.1.3. Increasing Investments and R&D Funding
3.2.1.4. Rising Prevalence of Rare and Genetic Disorders
3.2.2. Market Restraint Analysis
3.2.2.1. Recruitment Obstacles
3.3. Pricing Model Analysis
3.4. Technology Landscape
3.5. Market Analysis Tools
3.5.1. Porter’s Five Force Analysis
3.5.2. PESTEL by SWOT Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. U.S. Cell and Gene Therapy Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. U.S. Cell and Gene Therapy Clinical Trials Market, By Phase: Segment Dashboard
4.2. U.S. Cell and Gene Therapy Clinical Trials Market, By Phase: Movement Analysis
4.3. U.S. Cell and Gene Therapy Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
4.4. Phase I
4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Phase II
4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Phase III
4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Cell and Gene Therapy Clinical Trials Market: Indication Estimates & Trend Analysis
5.1. U.S. Cell and Gene Therapy Clinical Trials Market, By Indication: Segment Dashboard
5.2. U.S. Cell and Gene Therapy Clinical Trials Market, By Indication: Movement Analysis
5.3. U.S. Cell and Gene Therapy Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
5.4. Oncology
5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Cardiology
5.5.1. Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. CNS
5.6.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Musculoskeletal
5.7.1. Musculoskeletal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Infectious diseases
5.8.1. Infectious diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Dermatology
5.9.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Endocrine, metabolic, genetic
5.10.1. Endocrine, metabolic, genetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Immunology & inflammation
5.11.1. Immunology & inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12. Ophthalmology
5.12.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.13. Hematology
5.13.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.14. Gastroenterology
5.14.1. Gastroenterology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.15. Others
5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Company Market Share/Assessment Analysis, 2024
6.3. Company Profiles
6.3.1. IQVIA
6.3.1.1. Company Overview
6.3.1.2. Financial Performance
6.3.1.3. Service Benchmarking
6.3.1.4. Strategic Initiatives
6.3.2. ICON Plc
6.3.2.1. Company Overview
6.3.2.2. Financial Performance
6.3.2.3. Service Benchmarking
6.3.2.4. Strategic Initiatives
6.3.3. LabCorp
6.3.3.1. Company Overview
6.3.3.2. Financial Performance
6.3.3.3. Service Benchmarking
6.3.3.4. Strategic Initiatives
6.3.4. Charles River Laboratories
6.3.4.1. Company Overview
6.3.4.2. Financial Performance
6.3.4.3. Service Benchmarking
6.3.4.4. Strategic Initiatives
6.3.5. PAREXEL International Corp.
6.3.5.1. Company Overview
6.3.5.2. Financial Performance
6.3.5.3. Service Benchmarking
6.3.5.4. Strategic Initiatives
6.3.6. Syneos Health
6.3.6.1. Company Overview
6.3.6.2. Financial Performance
6.3.6.3. Service Benchmarking
6.3.6.4. Strategic Initiatives
6.3.7. Medpace
6.3.7.1. Company Overview
6.3.7.2. Financial Performance
6.3.7.3. Service Benchmarking
6.3.7.4. Strategic Initiatives
6.3.8. Thermo Fisher Scientific, Inc.
6.3.8.1. Company Overview
6.3.8.2. Financial Performance
6.3.8.3. Service Benchmarking
6.3.8.4. Strategic Initiatives
6.3.9. Novotech
6.3.9.1. Company Overview
6.3.9.2. Financial Performance
6.3.9.3. Service Benchmarking
6.3.9.4. Strategic Initiatives
6.3.10. Veristat, LLC
6.3.10.1. Company Overview
6.3.10.2. Financial Performance
6.3.10.3. Service Benchmarking
6.3.10.4. Strategic Initiatives
Chapter 7. Key Recommendations